PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29706998-0	2018	Melatonin Treatment Improves Insulin Resistance and Pigmentation in Obese Patients with Acanthosis Nigricans.	Melatonin	0-9	insulin	Homo sapiens	29-36	
29706998-1	2018	Objective: This study aimed to determine the effects of melatonin on insulin resistance in obese patients with acanthosis nigricans (AN).	Melatonin	56-65	insulin	Homo sapiens	69-76	
29706998-4	2018	Results: After 12 weeks of treatment with melatonin (3 mg/day), homeostasis model assessment insulin resistance index (HOMA-IR) (8.99 +- 5.10 versus 7.77 +- 5.21, p < 0.05) and fasting insulin (37.09 5 +- 20.26 muU/ml versus 32.10 +- 20.29 muU/ml, p < 0.05) were significantly decreased.	Melatonin	42-51	insulin	Homo sapiens	93-100	
29706998-4	2018	Results: After 12 weeks of treatment with melatonin (3 mg/day), homeostasis model assessment insulin resistance index (HOMA-IR) (8.99 +- 5.10 versus 7.77 +- 5.21, p < 0.05) and fasting insulin (37.09 5 +- 20.26 muU/ml versus 32.10 +- 20.29 muU/ml, p < 0.05) were significantly decreased.	Melatonin	42-51	insulin	Homo sapiens	188-195	
29706998-7	2018	Conclusions: It was concluded that melatonin could improve cutaneous symptoms in obese patients with acanthosis nigricans by improving insulin sensitivity and inflammatory status.	Melatonin	35-44	insulin	Homo sapiens	135-142